Prism Medico

Why is Prism Medico & Pharmacy Ltd falling/rising?

As of 16-Jul, Prism Medico & Pharmacy Ltd's stock price is at Rs 29.23, having increased by 3.65% today and showing strong year-to-date growth of 53.84%. Despite a decline in investor participation, the stock remains liquid and is trading above key moving averages, indicating a positive market sentiment.

As of 16-Jul, Prism Medico & Pharmacy Ltd's stock price is rising, currently at Rs 29.23, reflecting an increase of Rs 1.03 or 3.65%. The stock has shown strong performance today, outperforming its sector by 4.14% and has been on a gaining streak for the last two days, with a total return of 4.39% during this period. Notably, the stock opened with a significant gain of 4.96% today and reached an intraday high of Rs 29.6.<BR><BR>In terms of longer-term performance, Prism Medico has demonstrated impressive returns, with a year-to-date increase of 53.84%, significantly outperforming the Sensex, which has declined by 9.43% in the same timeframe. Over the past year, the stock has surged by 102.00%, while the Sensex has fallen by 6.59%. Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume dropping by 63.94% compared to the 5-day average. Despite this, the stock remains liquid enough for trading, suggesting that the current rise is supported by positive market sentiment and strong historical performance.

Which are the latest news on Prism Medico?

How big is Prism Medico?

As of 10th June, Prism Medico & Pharmacy Ltd has a market capitalization of 39.00 Cr, with net sales of 41.63 Cr and a net loss of 0.55 Cr over the latest four quarters. Shareholder's funds were 12.91 Cr, and total assets were 21.13 Cr as of March 2019.

As of 10th June, Prism Medico & Pharmacy Ltd has a market capitalization of 39.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported net sales of 41.63 Cr. However, it experienced a loss of 0.55 Cr in net profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2019, where shareholder's funds amounted to 12.91 Cr and total assets were reported at 21.13 Cr.

Who are in the management team of Prism Medico?

The management team of Prism Medico includes Sameer Gupta (Company Secretary & Compliance Officer), Ramandeep Singh and Sakshi Laller (Whole-time Directors), Simmi Chhabra and Pradeep Kumar (Independent Directors), and Davender Singh and Vishwambhar Dayal Gupta (Directors).

The management team of Prism Medico includes the following individuals:<BR><BR>1. Sameer Gupta - Company Secretary & Compliance Officer<BR>2. Ramandeep Singh - Whole-time Director<BR>3. Simmi Chhabra - Independent Director<BR>4. Davender Singh - Director<BR>5. Pradeep Kumar - Independent Director<BR>6. Sakshi Laller - Whole-time Director<BR>7. Vishwambhar Dayal Gupta - Director<BR><BR>If you need more specific information about their roles or contributions, feel free to ask!

Who are the peers of the Prism Medico?

Prism Medico's peers include Toyam Sports, Pan India Corpor, Madhusudan Sec., Anupam Finserv, Kiduja India, BSEL ALGO, HB Stockholdings, Key Corp, and Biogen Pharma. Prism Medico has a Below Average management risk and a 1-year return of 87.28%, significantly higher than its peers, many of which have negative returns.

Peers: The peers of Prism Medico are Toyam Sports, Pan India Corpor, Madhusudan Sec., Anupam Finserv, Kiduja India, BSEL ALGO, HB Stockholdings, Key Corp, and Biogen Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Madhusudan Sec. and Anupam Finserv, while Average management risk is found at Toyam Sports and Key Corp. Below Average management risk is noted at Prism Medico, BSEL ALGO, HB Stockholdings, Biogen Pharma, and Relic Tech., and the rest. Growth is Excellent at Madhusudan Sec., Good at BSEL ALGO, Below Average at Prism Medico, Toyam Sports, Anupam Finserv, and Biogen Pharma, and the rest do not qualify. Capital Structure is Excellent at Madhusudan Sec., Anupam Finserv, Toyam Sports, Key Corp, and HB Stockholdings, while Below Average is seen at Prism Medico, and the rest do not qualify.<BR><BR>Return Snapshot: Prism Medico has the highest 1-year return at 87.28%, while Biogen Pharma has the lowest at -64.95%. Compared to its peers, Prism Medico's return is significantly higher. Additionally, several peers, including Toyam Sports, Anupam Finserv, BSEL ALGO, HB Stockholdings, Key Corp, and Biogen Pharma, have negative six-month returns.

What does Prism Medico do?

Prism Medico and Pharmacy Ltd is a Micro Cap company in the NBFC sector, originally incorporated in 1985, with recent quarterly results showing net sales and profit of 0 Cr as of March 2026. The company has a market cap of INR 39 Cr and key metrics include a P/E of 115.00 and a return on equity of 2.19%.

Overview:<BR>Prism Medico and Pharmacy Ltd operates in the Non Banking Financial Company (NBFC) sector and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated as Woolite Mercantile Company Limited in 1985 and changed its name to Prism Medico and Pharmacy Limited on January 9, 2012. The latest quarterly results reported net sales and net profit of 0 Cr for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 39 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 115.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 2.19% <BR>Price to Book: 2.56 <BR><BR>Contact Details:<BR>Address: D-118 Industrial Area, Phase VII Mohali Punjab : 160055 <BR>Tel: 0172-5020762 <BR>Email: investorgrievancewmcl@gmail.com <BR>Website: http://www.prismmedico.in

Should I buy, sell or hold Prism Medico & Pharmacy Ltd?

Is Prism Medico overvalued or undervalued?

As of November 20, 2025, Prism Medico is considered undervalued with a valuation grade of very attractive, featuring a PE Ratio of 18.81, an EV to EBIT of 11.40, and a Price to Book Value of 0.76, significantly lower than peers like Max Healthcare and Apollo Hospitals, while maintaining a positive long-term outlook with a 3Y return of 77.32%.

As of 20 November 2025, Prism Medico's valuation grade has moved from fair to very attractive, indicating a significant improvement in its investment appeal. The company is currently considered undervalued. Key ratios include a PE Ratio of 18.81, an EV to EBIT of 11.40, and a Price to Book Value of 0.76, which suggest that the stock is trading at a discount relative to its earnings and book value.<BR><BR>In comparison to its peers, Prism Medico's PE Ratio of 18.81 is markedly lower than that of Max Healthcare, which stands at 80.46, and Apollo Hospitals at 63.94, both of which are classified as very expensive. Additionally, Prism Medico's EV to EBITDA ratio of 11.40 aligns with its valuation grade, reinforcing its attractiveness in the market. Despite recent underperformance against the Sensex, particularly in the 1Y and YTD periods, the long-term outlook remains positive with a 3Y return of 77.32%, suggesting potential for recovery and growth.

How has been the historical performance of Prism Medico?

Prism Medico experienced significant growth in net sales, rising from 5.28 Cr in Mar'17 to 54.73 Cr in Mar'19, but faced profitability challenges with a declining operating profit margin and a negative profit before tax in Mar'19. Total assets increased to 21.13 Cr, alongside rising liabilities, while cash flow remained stagnant with no reported activity.

Answer:<BR>The historical performance of Prism Medico shows significant growth in net sales over the years, increasing from 5.28 Cr in Mar'17 to 54.73 Cr in Mar'19. The total operating income followed a similar trend, rising from 5.28 Cr in Mar'17 to 54.73 Cr in Mar'19. However, the company has faced challenges with profitability, as indicated by the operating profit margin which decreased from 3.33% in Mar'18 to 0.73% in Mar'19, and the profit before tax turned negative at -0.10 Cr in Mar'19 after a positive 0.07 Cr in Mar'18. Despite these challenges, the profit after tax showed a slight recovery to 0.04 Cr in Mar'19 from a loss in the previous years. The total assets increased from 17.26 Cr in Mar'17 to 21.13 Cr in Mar'19, while total liabilities also rose from 15.80 Cr in Mar'18 to 21.13 Cr in Mar'19, indicating a growing financial base but also increasing obligations. The cash flow results indicate no cash inflow or outflow from operating, investing, or financing activities for the years reported.<BR><BR>Breakdown:<BR>Prism Medico's financial performance has demonstrated a remarkable increase in net sales, which surged from 5.28 Cr in Mar'17 to 54.73 Cr in Mar'19, reflecting a strong growth trajectory. The total operating income mirrored this growth, reaching 54.73 Cr in Mar'19. However, the company struggled with profitability, as evidenced by a decline in operating profit margin from 3.33% in Mar'18 to 0.73% in Mar'19, and a negative profit before tax of -0.10 Cr in Mar'19, contrasting with a profit of 0.07 Cr in the prior year. Despite these setbacks, the profit after tax improved to 0.04 Cr in Mar'19, following losses in earlier years. On the balance sheet, total assets rose from 17.26 Cr in Mar'17 to 21.13 Cr in Mar'19, while total liabilities increased correspondingly from 15.80 Cr to 21.13 Cr, indicating a growing but leveraged financial position. The cash flow statements reveal no activity in cash flows from operations, investments, or financing, suggesting a stagnant cash position during this period.

When is the next results date for Prism Medico?

The next results date for Prism Medico is 14 November 2025.

The next results date for Prism Medico is scheduled for 14 November 2025.

Are Prism Medico latest results good or bad?

Prism Medico's latest results are concerning, showing flat performance for Q4 2024 and a 'Strong Sell' rating from MarketsMOJO. However, there are signs of improvement with significant growth in net sales and profit projected for the next quarter, indicating potential for a turnaround.

Prism Medico's latest financial results indicate a challenging situation. The company reported flat performance for the fourth quarter of 2024, showing no significant changes in its financial metrics. This stagnation has led to a 'Strong Sell' rating from MarketsMOJO, suggesting that the market perceives potential difficulties in the company's growth and operational efficiency.<BR><BR>However, looking ahead, there are signs of improvement in the subsequent quarter ending June 2025. The company experienced a remarkable increase in net sales and standalone net profit, with growth rates of 2,171.43% and 1,550.00%, respectively. This upward trend in financial performance could signal a turnaround, but the initial flat results raise concerns about the company's ability to sustain this momentum.<BR><BR>Overall, while the recent quarterly results are not favorable, the significant growth in the following quarter may provide a glimmer of hope for stakeholders. It will be essential to monitor how Prism Medico navigates its challenges in the evolving healthcare sector.

What is the technical trend for Prism Medico?

As of May 19, 2025, Prism Medico's technical trend is mildly bearish, with mixed signals across time frames from MACD, moving averages, and Bollinger Bands, indicating a lack of strong momentum.

As of 19 May 2025, the technical trend for Prism Medico has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are mildly bearish, suggesting short-term weakness. Bollinger Bands show a bullish signal on the weekly chart but a mildly bearish signal on the monthly chart, indicating mixed signals across time frames. The KST is mildly bullish weekly but bearish monthly, further contributing to the overall mildly bearish outlook. The Dow Theory shows no clear trend in both weekly and monthly views. Overall, the current technical stance is mildly bearish, reflecting a lack of strong momentum in either direction.

Who are the top shareholders of the Prism Medico?

The top shareholders of Prism Medico are Symbiosis Pharmaceutical Private Limited with 13.99%, followed by public shareholder Vinita Jain at 4.83%. Individual investors collectively own 66.07% of the shares, with no institutional or pledged promoter holdings reported.

The top shareholders of Prism Medico include Symbiosis Pharmaceutical Private Limited, which holds the largest stake at 13.99%. Following that, the highest public shareholder is Vinita Jain, with a holding of 4.83%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 66.07% of the shares. There are no institutional holdings or pledged promoter holdings reported.

Has Prism Medico declared dividend?

No Dividend History Available